Evidence map›Paper›PMID 42167807›Full record

SynthesisJournal of nuclear medicine : official publication, Society of Nuclear Medicine2026

Assessing Value for Money in Theranostic Nuclear Medicine: A Systematic Review.

Yufan Wang, James L Wood, Kristofer J Thurecht, Su Yu Yeoh, Haitham Tuffaha

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yufan WangCentre for the Business and Economics of Health, The University of Queensland, Brisbane, Queensland, Australia.
James L WoodAustralian Research Council Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals, The University of Queensland, Brisbane, Queensland, Australia; and.
Kristofer J ThurechtAustralian Research Council Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals, The University of Queensland, Brisbane, Queensland, Australia; and.
Su Yu YeohCentre for the Business and Economics of Health, The University of Queensland, Brisbane, Queensland, Australia.
Haitham TuffahaCentre for the Business and Economics of Health, The University of Queensland, Brisbane, Queensland, Australia; h.tuffaha@uq.edu.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiotheranostic therapy (RTT) is an emerging form of personalized cancer care that combines radiopharmaceutical imaging and radiopharmaceutical therapy (RPT). Although promising clinically, the value for money of RTT remains uncertain. The objective of this study is to review the cost-effectiveness evidence of RTT in cancer and critically appraise the methodologies utilized in conducting the included economic evaluations.

Indexed as

Nuclear MedicineTheranostic NanomedicineCost-Benefit AnalysisCost-Effectiveness AnalysisHumansNeoplasmsRadiopharmaceuticalsRadiopharmaceuticalscancercost-effectivenesseconomic evaluationhealth technology assessmentnuclear medicineoncologyradiopharmaceuticalstheranostics

Identifiers

PMID42167807
PMCPMC13435547

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.